Efficacy and safety of teriflunomide in chinese patients with relapsing forms of ms: a subgroup analysis of the phase 3 tower study

Conclusions In Chinese patients enrolled in TOWER, teriflunomide 14 mg reduced ARR and risk of 12 w-CDW vs placebo; the small number of patients in this subgroup may have contributed to the lack of statistical significance observed for 12 w-CDW. However, there was a consistency of outcomes between the Chinese subpopulation and the overall TOWER population in terms of efficacy and safety. Study supported by Sanofi Genzyme.
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Tags: Abstracts Source Type: research